How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
LONDON and STONY BROOK, N.Y., Feb. 1 /PRNewswire-FirstCall/ -- Medicsight PLC, a majority owned subsidiary of Medicsight, Inc. (AMEX: MGT) and a leading developer of computer-aided detection (CAD) technologies and software, and Viatronix Inc., a Stony Brook, New York-based industry leader in 2D/3D clinical solutions, announced today that Medicsight ColonCAD, integrated as part of the Viatronix V3D-Colon workstation, will be used in the SIGGAR1 clinical trial to interpret CT colonography (virtual colonoscopy) studies. Vertec Scientific, a Viatronix U.K. sales and service provider, will install the combined Viatronix/Medicsight imaging systems into all 15 SIGGAR1 trial sites around the U.K.
The multi-center SIGGAR1 trial, conducted by the Special Interest Group for Gastrointestinal and Abdominal Radiology (SIGGAR) and sponsored by the National Health Service (NHS) Health Technology Assessment (HTA) program, aims to compare CT colonography with the two established alternatives, barium enema and optical colonoscopy, for diagnosis of colonic cancer in older symptomatic patients in the United Kingdom. While many studies have shown CT colonography to be very sensitive for colon cancer, the SIGGAR1 trial is the first randomized trial to investigate this modality against traditional colonoscopy and barium enema. The SIGGAR1 trial will include approximately 4,500 patients, and results are expected to be reported in 2008.
"A well-recognized problem for large trials, especially those that depend on high technology, is that their results can be considered out of date by the time they report if their protocol is not sufficiently flexible to allow them to 'move with the times.' Our studies strongly suggest that CAD seamlessly integrated into CT Colonography software helps to reduce the time needed to report CT colonography while simultaneously improving sensitivity for polyps and cancers. The SIGGAR1 trial offers a significant opportunity to test these findings at multiple sites across multiple observers to see if they are reproducible. It is expected that Viatronix V3D-Colon workstations with integrated Medicsight ColonCAD will be available at some sites early in 2006, when a sub-study of the effect of CAD on the detection of cancers and large polyps (i.e. those possibly responsible for symptoms) will begin in earnest," said Professor Steve Halligan, principal investigator for SIGGAR1 and consultant radiologist at University College Hospital, London.
"We are extremely pleased to have the SIGGAR1 trial use the first fully integrated system that seamlessly incorporates ColonCAD and CT Colonography," said Zaffar Hayat, president and CEO, Viatronix Inc. Jonah Aburrow-Jones, commercial development director, Medicsight, added, "Medicsight and Viatronix are committed to being at the forefront of medical imaging analysis in CT Colonography and detection of colorectal cancer, which makes our participation in the SIGGAR1 trial a natural fit." Both companies plan to launch integrated software in Europe next month and will work closely together in other clinical trial programs in the United States and Europe as well as support clinical education for CT Colonography.
The Viatronix V3D-Colon workstation with Medicsight ColonCAD API allows users of the integrated software to simultaneously view Medicsight ColonCAD polyp identification marks while viewing a virtual fly-through of the colon. Filter settings also can be manually altered to suit the user's preference, clinical situation, and experience.